cardiac targeting peptide cardiac-targeting peptides - Inhalation of peptide-loaded nanoparticles improves heart failure target Cardiac Targeting Peptide: A Novel Vector for Heart-Specific Delivery

In vivo phage display A cardiac targeting peptide (CTP) represents a specialized class of peptides engineered to selectively bind to and enter cells within the heartNew peptide targets the root causes of recurring seizures. These peptides, often short chains of amino acids, are designed to overcome biological barriers and deliver therapeutic agents or imaging probes directly to cardiomyocytes and cardiac fibroblasts. The ability of CTPs to achieve targeted delivery to the heart offers significant potential for advancing cardiovascular disease treatment and diagnostics, aiming to enhance efficacy while minimizing off-target effects.Toxicity Studies of Cardiac-Targeting Peptide Reveal a ...

The development of cardiac targeting peptides stems from the need for more precise methods to treat or diagnose heart conditions. Traditional systemic drug administration often results in the therapeutic agent being distributed throughout the body, leading to potential side effects and reduced concentration at the intended site of action.US9249184B2 - Cardiac-specific protein targeting domain CTPs, by contrast, act as sophisticated delivery vehicles, guiding therapeutic payloads specifically to the cardiac tissue. Research has identified various CTPs, with some being synthetic, non-naturally occurring peptides, such as a notable 12-amino acid peptide that demonstrates high specificity for cardiac tissue.

Mechanisms and Properties of Cardiac Targeting Peptides

Cardiac targeting peptides function primarily through their ability to recognize and interact with specific receptors or molecular markers that are overexpressed on the surface of cardiomyocytes or within cardiac cells. This specific binding is crucial for their targeted action. Once bound, many CTPs act as cell-penetrating peptides (CPPs), a broader category of peptides characterized by their capacity to traverse cell membranes. This cell-penetrating capability allows the CTP, along with any attached cargo, to enter the cell.

The size of these peptides is typically small, ranging from approximately 6 to 30 amino acids long. This compact structure is often advantageous for cellular uptake and biodistribution. For instance, a specific 12-amino acid peptide has shown peak uptake in the heart as early as 15 minutes after intravenous injection, highlighting its rapid and efficient cardiac targeting. Modifications to CTPs, such as incorporating D-amino acids at specific positions, can further enhance their targeting ability and stability within the cardiac environment, particularly under pathological conditions like heart failure, where they have been shown to promote targeting of cardiomyocytes and fibroblasts作者：M Chen·2024·被引用次数：19—Exosomes were labeled with either aCardiacHomingPeptide(CTP, CSTSMLKAC), which is known to specificallytargetthe infarct heart, or a Scramblepeptide(Scr ....

Applications and Future Directions

The primary application of cardiac targeting peptides lies in their use as vectors for targeted drug delivery. By conjugating therapeutic molecules to CTPs, researchers aim to deliver potent drugs directly to the heart, potentially revolutionizing the treatment of conditions such as heart failure, hypertrophy, and other cardiac diseases.Cell-penetrating peptides (CPPs), also known as protein transduction domains, were first identified 25 years ago.They are small, ~6–30 amino acid long, ... For example, CTPs have been explored for delivering miRNA106a, a molecule that targets genes involved in cardiac hypertrophy, offering a novel approach to reversing the condition.

Beyond therapeutic delivery, CTPs also hold promise in cardiac imaging. Their specific targeting allows for the visualization of cardiac tissue or pathological processes with greater clarity and precision.Toxicity Studies of Cardiac Targeting Peptide Reveal a ... Furthermore, the development of CTP-functionalized delivery systems, such as liposomes, aims to create even more sophisticated methods for delivering treatments directly to cardiomyocytes.

Research is ongoing to further understand the mechanisms by which CTPs internalize into cardiomyocytes, with some studies suggesting the involvement of voltage-gated calcium channels. The safety and efficacy of CTPs are also critical areas of investigation, with studies indicating that CTPs can be safe and effective technologies for delivering therapeutic cargoes to cardiomyocytes, showing no overt toxicity in certain tested models. The exploration of novel peptides through methods like in vivo phage display continues to uncover new candidates with enhanced cardiac targeting capabilities, paving the way for more advanced cardiovascular therapies.